Text Size

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase i Study)

Aihara M., Lu F., Kawata H., Tanaka Y., Yamamura K., Odani-Kawabata N., Shams N.K.


  • 2019
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, University of Tokyo, Bunkyo-ku, Japan; Santen Inc., 6401 Hollis Street, Emeryville, CA 94608, United States; Santen Pharmaceutical Co Ltd., Osaka, Japan; Santen Pharmaceutical Co Ltd., Ikoma, Japan

Related Publications

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM


MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022